靶向治疗巨噬细胞可塑性重塑肿瘤免疫微环境。
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.
机构信息
Systems Onco-Immunology Laboratory, The David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Department of Pathology/Laboratory Medicine, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Cancer Res. 2022 Jul 18;82(14):2593-2609. doi: 10.1158/0008-5472.CAN-21-3506.
Abstract
Comprehensive single-cell proteomics analyses of lung adenocarcinoma progression reveal the role of tumor-associated macrophages in resistance to PD-1 blockade therapy. See related commentary by Lee et al., p. 2515.
摘要
全面的单细胞蛋白质组学分析揭示了肺腺癌进展中肿瘤相关巨噬细胞在 PD-1 阻断治疗耐药中的作用。详见 Lee 等人的相关述评，第 2515 页。
相似文献
1
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.靶向治疗巨噬细胞可塑性重塑肿瘤免疫微环境。
Cancer Res. 2022 Jul 18;82(14):2593-2609. doi: 10.1158/0008-5472.CAN-21-3506.
2
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.上皮-间质转化与独特的肿瘤微环境相关，包括肺腺癌中炎症信号的升高和多个免疫检查点。
Clin Cancer Res. 2016 Jul 15;22(14):3630-42. doi: 10.1158/1078-0432.CCR-15-1434. Epub 2016 Feb 5.
3
Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.非吸烟肺腺癌患者肿瘤微环境不良预后免疫特征的测定
Eur J Cancer. 2017 Nov;86:15-27. doi: 10.1016/j.ejca.2017.08.026. Epub 2017 Sep 23.
4
A lncRNA signature of tumor-infiltrating macrophages is associated with prognosis and tumor immunity in lung adenocarcinoma.肿瘤浸润性巨噬细胞的 lncRNA 特征与肺腺癌的预后和肿瘤免疫相关。
Comput Biol Med. 2022 Sep;148:105655. doi: 10.1016/j.compbiomed.2022.105655. Epub 2022 May 21.
5
Preinvasive to Invasive: PD-1-Expressing Macrophages Shift Lung Cancer into High Gear.从癌前病变到浸润性癌：表达PD-1的巨噬细胞使肺癌加速发展。
Cancer Res. 2022 Jul 18;82(14):2515-2516. doi: 10.1158/0008-5472.CAN-22-1802.
6
Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.肿瘤相关巨噬细胞浸润与早期肺腺癌中肿瘤程序性死亡配体 1 的表达有关。
Cancer Sci. 2020 Feb;111(2):727-738. doi: 10.1111/cas.14272. Epub 2020 Jan 6.
7
Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.携带表皮生长因子受体突变的实性为主型肺腺癌亚型的侵袭性肿瘤微环境。
Lung Cancer. 2016 Jan;91:7-14. doi: 10.1016/j.lungcan.2015.11.012. Epub 2015 Nov 15.
8
NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.NRAS 表达与肺腺癌的预后和肿瘤免疫微环境相关。
J Cancer Res Clin Oncol. 2022 Mar;148(3):565-575. doi: 10.1007/s00432-021-03842-w. Epub 2021 Nov 8.
9
USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.USP7 靶向调控通过重编程肺癌中的肿瘤相关巨噬细胞来调节抗肿瘤免疫反应。
Theranostics. 2020 Jul 23;10(20):9332-9347. doi: 10.7150/thno.47137. eCollection 2020.
10
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.程序性细胞死亡配体 1 在肺腺癌切除标本中的表达：与免疫微环境的关联。
J Thorac Oncol. 2016 Nov;11(11):1869-1878. doi: 10.1016/j.jtho.2016.08.134. Epub 2016 Aug 24.
引用本文的文献
1
NFATC3 enhances osteosarcoma progression by increasing PD-L1 and CXCL2 levels.NFATC3通过提高PD-L1和CXCL2水平促进骨肉瘤进展。
Med Oncol. 2025 Jul 29;42(9):388. doi: 10.1007/s12032-025-02850-x.
2
Traditional Chinese medicine in the prevention and treatment of lung cancer metastasis by regulating tumor-associated macrophages: a narrative review.传统中医通过调节肿瘤相关巨噬细胞预防和治疗肺癌转移：一项叙述性综述
Transl Lung Cancer Res. 2025 Jun 30;14(6):2281-2295. doi: 10.21037/tlcr-2025-380. Epub 2025 Jun 26.
3
Blocking M2-Like Macrophage Polarization Using Decoy Oligodeoxynucleotide-Based Gene Therapy Prevents Immune Evasion for Pancreatic Cancer Treatment.使用基于寡核苷酸的基因治疗阻断 M2 样巨噬细胞极化可预防胰腺癌治疗中的免疫逃逸。
Mol Cancer Ther. 2024 Oct 1;23(10):1431-1445. doi: 10.1158/1535-7163.MCT-23-0767.
4
Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing.利用单细胞RNA测序解析肺腺癌的肿瘤免疫微环境
Ther Adv Med Oncol. 2024 Apr 10;16:17588359231210274. doi: 10.1177/17588359231210274. eCollection 2024.
5
Alveolar macrophages in lung cancer: opportunities challenges.肺癌中的肺泡巨噬细胞：机遇与挑战
Front Immunol. 2023 Sep 26;14:1268939. doi: 10.3389/fimmu.2023.1268939. eCollection 2023.
6
Heterogeneity of the tumor immune microenvironment and clinical interventions.肿瘤免疫微环境的异质性与临床干预
Front Med. 2023 Aug;17(4):617-648. doi: 10.1007/s11684-023-1015-9. Epub 2023 Sep 20.
7
Innate Immune Memory in Macrophages.巨噬细胞中的固有免疫记忆
Newborn (Clarksville). 2023 Jan-Mar;2(1):60-79. doi: 10.5005/jp-journals-11002-0058. Epub 2023 Apr 6.
8
Tumor-associated macrophages in direct contact with prostate cancer cells promote malignant proliferation and metastasis through NOTCH1 pathway.肿瘤相关巨噬细胞与前列腺癌细胞直接接触，通过 NOTCH1 通路促进恶性增殖和转移。
Int J Biol Sci. 2022 Oct 3;18(16):5994-6007. doi: 10.7150/ijbs.73141. eCollection 2022.
本文引用的文献
1
Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy.Trabectedin 通过抑制肿瘤相关巨噬细胞来改善抗 PD-1 治疗的抗肿瘤适应性免疫。
Eur J Immunol. 2021 Nov;51(11):2677-2686. doi: 10.1002/eji.202149379. Epub 2021 Oct 8.
2
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.癌症干细胞的起源和生物标志物：靶向个体化治疗的新视角。
Front Immunol. 2020 Aug 7;11:1280. doi: 10.3389/fimmu.2020.01280. eCollection 2020.
4
Acquired Resistance to Immune Checkpoint Inhibitors.获得性免疫检查点抑制剂耐药。
Cancer Cell. 2020 Apr 13;37(4):443-455. doi: 10.1016/j.ccell.2020.03.017.
5
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.预测抗 PD-1 免疫疗法在非小细胞肺癌患者中持久临床获益的免疫基因特征。
Sci Rep. 2020 Jan 20;10(1):643. doi: 10.1038/s41598-019-57218-9.
6
Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors.基于转录组的非小细胞肺癌分子亚型可能预测对免疫检查点抑制剂的反应。
J Thorac Cardiovasc Surg. 2020 Apr;159(4):1598-1610.e3. doi: 10.1016/j.jtcvs.2019.10.123. Epub 2019 Nov 11.
7
Genomic and immune profiling of pre-invasive lung adenocarcinoma.肺浸润前腺癌的基因组和免疫特征分析。
Nat Commun. 2019 Nov 29;10(1):5472. doi: 10.1038/s41467-019-13460-3.
8
CytoNorm: A Normalization Algorithm for Cytometry Data.CytoNorm：一种流式细胞术数据标准化算法。
Cytometry A. 2020 Mar;97(3):268-278. doi: 10.1002/cyto.a.23904. Epub 2019 Oct 21.
9
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.肺浸润前和早期浸润性腺癌的基因组景观和免疫微环境特征。
J Thorac Oncol. 2019 Nov;14(11):1912-1923. doi: 10.1016/j.jtho.2019.07.031. Epub 2019 Aug 22.
10
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.纳武利尤单抗治疗既往治疗的晚期非小细胞肺癌患者的 4 年生存：汇总分析。
Lancet Oncol. 2019 Oct;20(10):1395-1408. doi: 10.1016/S1470-2045(19)30407-3. Epub 2019 Aug 14.
Zotero 插件